Skip to main content
PMC home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2003 Jul 30;4(3):101–109. doi: 10.1208/pt040342

Effect of polyols on the conformational stability and biological activity of a model protein lysozyme

Somnath Singh 1,2,✉, Jagdish Singh 1
PMCID: PMC2750635  PMID: 14621974

Abstract

The purpose of this study was to investigate the stabilizing action of polyols against various protein degradation mechanisms (eg, aggregation, deamidation, oxidation), using a model protein lysozyme. Differential scanning calorimeter (DSC) was used to measure the thermodynamic parameters, mid point transition temperature and calorimetric enthalpy, in order to evaluate conformational stability. Enzyme activity assay was used to corroborate the DSC results. Mannitol, sucrose, lactose, glycerol, and propylene glycol were used as polyols to stabilize lysozyme against aggregation, deamidation, and oxidation. Mannitol was found to stabilize lysozyme against aggregation, sucrose against deamidation both at neutral pH and at acidic pH, and lactose against oxidation. Stabilizers that provided greater conformational stability of lysozyme against various degradation mechanisms also protected specific enzyme activity to a greater extent. It was concluded that DSC and bioassay could be valuable tools for screening stabilizers in protein formulations.

Keywords: differential scanning calorimeter, protein conformational stability, polyols, enzyme activity assay, lysozyme

Full Text

The Full Text of this article is available as a PDF (512.0 KB).

References

  • 1.Lee HJ. Protein drug oral delivery: the recent progress. Arch Pharm Res. 2002;25:572–584. doi: 10.1007/BF02976925. [DOI] [PubMed] [Google Scholar]
  • 2.Jen A, Merkle HP. Diamonds in the rough protein crystals from a formulation perspective. Pharm Res. 2001;18:1483–1488. doi: 10.1023/A:1013057825942. [DOI] [PubMed] [Google Scholar]
  • 3.DiBiase MD, Kottke MK. Stability of polypeptides and proteins. In: Carstensen JT, Rhodes CT, editors. Drugs and the Pharmaceutical Sciences, Drug Stability. New York, NY: Marcel Dekker; 2000. pp. 853–874. [Google Scholar]
  • 4.Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol. 2001;12:212–219. doi: 10.1016/S0958-1669(00)00202-0. [DOI] [PubMed] [Google Scholar]
  • 5.Cleland JL, Powell MF, Shire JS. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst. 1993;10:307–377. [PubMed] [Google Scholar]
  • 6.Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185:129–188. doi: 10.1016/S0378-5173(99)00152-0. [DOI] [PubMed] [Google Scholar]
  • 7.Xie M, Schowen R. Secondary structure and protein deamidation. J Pharm Sci. 1999;88:8–13. doi: 10.1021/js9802493. [DOI] [PubMed] [Google Scholar]
  • 8.Daniel RM, Dines M, Petach HH. The denaturation and degradation of stable enzymes at higher temperature. Biochem J. 1996;317:1–11. doi: 10.1042/bj3170001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Li S, Schoneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: Mechanism of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48:490–500. doi: 10.1002/bit.260480511. [DOI] [PubMed] [Google Scholar]
  • 10.Bummer PM, Koppenol S. Chemical and physical considerations in protein and peptide stability. In: McNally EJ, editor. Drugs and the Pharmaceutical Sciences, Protein Formulation and Delivery. New York, NY: Marcel Dekker; 2000. pp. 15–18. [Google Scholar]
  • 11.Stoll VS, Blanchard JS. Buffers: principles and practice. In: Deutscher M, Abelson J, editors. Guide to Protein Purification: Methods in Enzymology (Methods in Enzymology Series) London, UK: Academic Press; 1990. pp. 24–37. [Google Scholar]
  • 12.Shugar D. The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. Biochim Biophys Acta. 1952;8:302–309. doi: 10.1016/0006-3002(52)90045-0. [DOI] [PubMed] [Google Scholar]
  • 13.Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  • 14.Richard L, Remmele RL, Nancy SN, Subhashini S, Wayne RG. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res. 1998;15:200–208. doi: 10.1023/A:1011902215383. [DOI] [PubMed] [Google Scholar]
  • 15.Azuaga AI, Dobson CM, Mateo PL, Conejero LF. Unfolding and aggregation during the thermal denaturation of streptokinase. Eur J Biochem. 2002;269:4121–4133. doi: 10.1046/j.1432-1033.2002.03107.x. [DOI] [PubMed] [Google Scholar]
  • 16.Barone G, Catanzano F, Vecchio P, Giancola C, Graziano G. Thermodynamics of protein stability: a family of ribonucleases. Pure Appl Chem. 1997;69:2307–2313. doi: 10.1351/pac199769112307. [DOI] [Google Scholar]
  • 17.Komsa PR, Koynova R, Kostov G, Tenchov B. Discrete reduction of type 1 collagen thermal stability upon oxidation. Biophys Chem. 2000;83:185–195. doi: 10.1016/S0301-4622(99)00135-0. [DOI] [PubMed] [Google Scholar]
  • 18.Sebastien B, Forbes RT, York P, Nyqvist H. A central composite design to investigate the thermal stabilization of lysozyme. Pharm Res. 1999;16:702–708. doi: 10.1023/A:1018876625126. [DOI] [PubMed] [Google Scholar]
  • 19.Chang BS, Randall CS, Lee YS. Stabilization of lyophilized porcine pancreatic elastase. Pharm Res. 1993;10:1478–1483. doi: 10.1023/A:1018979410338. [DOI] [PubMed] [Google Scholar]
  • 20.Johnson CM, Cooper A, Stockley PG. Differential scanning calorimetry of thermal unfolding of the methionine repressor protein (MetJ) from Escherichia coli. Biochemistry. 1992;31:9717–9724. doi: 10.1021/bi00155a027. [DOI] [PubMed] [Google Scholar]
  • 21.Kenar KT, Garcia-Moreno B, Freire EA. Calorimetric characterization of the salt dependence of the stability of the GCN4 leucine zipper. Protein Sci. 1995;4(9):1934–1938. doi: 10.1002/pro.5560040929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Son K, Kwon C. Stabilization of human epidermal growth factor (hEGF) in aqueous formulation. Pharm Res. 1995;12:451–454. doi: 10.1023/A:1016225207014. [DOI] [PubMed] [Google Scholar]
  • 23.Shire SJ. Stability characterization and formulation development of recombinant human deoxyribonuclease I (Pulmozyme, [dornase alpha]) In: Pearlman R, Wang YJ, editors. Formulation, Characterization, and Stability of Protein Drugs. New York, NY: Plenum Press; 1996. pp. 393–426. [DOI] [PubMed] [Google Scholar]
  • 24.Cross RT, Schirch V. Effect of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptide. J Biol Chem. 1991;266:22549–22556. [PubMed] [Google Scholar]
  • 25.Voet D, Voet JG. Biochemistry. New York, NY: John Wiley & Sons, Inc; 1995. pp. 381–383. [Google Scholar]
  • 26.Powell MF. A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: reactivity at Asn, Asp, Gln, and Met motifs in neutral pH solution. In: Pearlman R, Wang YJ, editors. Formulation, Characterization, and Stability of Protein Drugs. New York, NY: Plenum Press; 1996. pp. 1–140. [Google Scholar]
  • 27.Patel K, Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res. 1990;7:703–711. doi: 10.1023/A:1015807303766. [DOI] [PubMed] [Google Scholar]
  • 28.Oliyai C, Borchardt RT. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an asparyl residue in a model hexapeptide. Pharm Res. 1993;10:95–102. doi: 10.1023/A:1018981231468. [DOI] [PubMed] [Google Scholar]
  • 29.Richards FM. Protein stability: still an unsolved problem. Cell Mol Life Sci. 1997;53:790–802. doi: 10.1007/s000180050100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kang F, Jiang G, Hinderliter A, DeLuca PP, Singh J. Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res. 2002;19:629–633. doi: 10.1023/A:1015354028908. [DOI] [PubMed] [Google Scholar]
  • 31.Capan Y, Jiang G, Giovagnoli S, Na K-H, DeLuca PP. Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone. AAPS Pharm Sci Tech. 2003;4(2);article 28. [DOI] [PMC free article] [PubMed]
  • 32.Prestrelski SJ, Tedeschi N, Arakawa T, Carpenter JF. Dehydration-induced conformational changes in proteins and their inhibition by stabilizers. Biophys J. 1993;65:661–671. doi: 10.1016/S0006-3495(93)81120-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Allison SD, Chang B, Randolph TW, Carpenter JF. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch Biochem Biophys. 1999;365:289–298. doi: 10.1006/abbi.1999.1175. [DOI] [PubMed] [Google Scholar]
  • 34.Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci U S A. 1997;94:11917–11922. doi: 10.1073/pnas.94.22.11917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Lee JC, Timasheff SN. The stabilization of proteins by sucrose. J Biol Chem. 1981;256:7193–7201. [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES